Hypertension
Peptides discussed in hypertension — ANP, BNP — with honest framing about why they are biomarkers rather than therapy, what conventional antihypertensive medications remain, and where peptide-related research is heading.
Hypertension is the most common modifiable cardiovascular risk factor, affecting roughly 47% of US adults and a comparable proportion globally. The condition is largely silent until end-organ damage develops, and chronic hypertension drives heart disease, stroke, kidney disease, and accelerated cognitive decline. The treatment landscape is one of medicine's most evidence-validated: lifestyle modification (DASH diet, reduced sodium, weight optimization, aerobic exercise, alcohol moderation) plus pharmacological therapy (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics, beta-blockers in selected patients, mineralocorticoid receptor antagonists, renal denervation in resistant cases) reduces cardiovascular events meaningfully. The SPRINT and HOPE-3 trials established that aggressive blood pressure targets reduce cardiovascular outcomes.
Peptide therapy for hypertension is mostly NOT what people imagine when they search this term. Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are endogenous peptides released by the heart in response to volume overload, with vasodilatory and natriuretic effects. They are extensively used clinically as biomarkers — BNP and NT-proBNP are routine in heart failure diagnosis and management. The synthetic recombinant BNP (nesiritide) was briefly used as IV therapy for acute decompensated heart failure but largely withdrawn after the ASCEND-HF trial showed limited benefit.
For primary hypertension treatment, peptides have a limited role. The honest framing: peptides do not replace ACE inhibitors, ARBs, or other evidence-validated antihypertensives. ANP and BNP analogs have not entered widespread clinical use as antihypertensive therapy. Some research peptides target related pathways (apelin, urodilatin, others) but remain investigational. This page covers the honest peptide-related landscape in hypertension and the substantial evidence base for conventional therapy that should not be substituted with peptide-only approaches.
This page is informational, not medical advice. Hypertension management requires evidence-based clinical care.
Peptides discussed for Hypertension
BNP
Natriuretic Peptide
An endogenous 32-amino-acid cardiac hormone secreted primarily by ventricular myocytes in response to wall stretch — the dominant natriuretic peptide in clinical practice and the basis of the BNP and NT-proBNP assays used worldwide for heart failure diagnosis, risk stratification, and management.
C-Type Natriuretic Peptide
Natriuretic Peptide
An endogenous 22-amino-acid peptide identified in 1990 by Sudoh, Minamino, Kangawa, and Matsuo as the third member of the natriuretic peptide family. Unlike ANP and BNP, CNP is predominantly endothelial and chondrocytic rather than cardiac, signals through NPR-B (not NPR-A), and is the master driver of endochondral long-bone growth — the biology that vosoritide (Voxzogo) was engineered to mimic for achondroplasia.
ANP
Natriuretic Peptide
An endogenous 28-amino-acid cardiac hormone secreted by atrial myocytes in response to wall stretch; drives natriuresis, vasodilation, and renin-aldosterone suppression. Approved in Japan as carperitide (recombinant human ANP) for acute decompensated heart failure since 1995, but never FDA-approved in the United States.
Apelin
Endogenous APJ Receptor Ligand
An endogenous peptide hormone and ligand of the APJ receptor with positive inotropic, vasodilatory, and insulin-sensitizing effects — heavily studied as a heart-failure target but not available as an approved therapy, with small-molecule APJ agonists now advancing through early clinical trials.
How peptides target hypertension
ANP (atrial natriuretic peptide) is released from atrial cardiomyocytes in response to atrial wall stretch (volume overload). Its actions include vasodilation, natriuresis (sodium excretion), reduced renin release, and inhibition of aldosterone — all mechanistically aligned with reducing volume and blood pressure. Synthetic recombinant ANP (carperitide) is approved in Japan for acute decompensated heart failure but has not entered widespread use elsewhere.
BNP (B-type natriuretic peptide) has similar actions, released primarily from ventricular cardiomyocytes in response to ventricular stretch. Synthetic recombinant BNP (nesiritide, Natrecor) was FDA-approved for acute decompensated heart failure in 2001 but largely fell out of use after the 2011 ASCEND-HF trial showed limited symptom benefit and concerns about renal function and survival. BNP and NT-proBNP remain widely used as biomarkers for diagnosis and management of heart failure.
Apelin and urodilatin are related natriuretic peptides under research interest. Apelin agonists are in development for heart failure with various trial programs. Urodilatin (a renal-derived natriuretic peptide) has limited clinical use. Sacubitril (in combination with valsartan as Entresto) inhibits neprilysin to prolong endogenous natriuretic peptide activity — an indirect peptide-pathway intervention that has revolutionized heart failure treatment.
What peptides do not do for primary hypertension: replace ACE inhibitors, ARBs, calcium channel blockers, or other evidence-validated antihypertensives; provide chronic blood pressure control; modify cardiovascular outcomes in primary hypertension comparable to established therapy; offer convenient outpatient hypertension management.
What the evidence shows
For primary hypertension, peptide therapy has essentially no place beyond research interest. The evidence-validated treatment landscape is enormous: hundreds of RCTs supporting ACE inhibitors, ARBs, calcium channel blockers, thiazides, and other antihypertensives. The SPRINT trial (2015) established that aggressive blood pressure targets (<120/80 mmHg in selected patients) reduce cardiovascular events. The HOPE-3 trial in lower-risk patients also showed benefit of aggressive treatment.
For heart failure (where natriuretic peptide pathway interventions are most relevant): ARNI therapy (sacubitril/valsartan) revolutionized treatment based on the PARADIGM-HF trial. SGLT2 inhibitors entered heart failure treatment based on multiple trials. Beta-blockers, MRAs, and ARBs/ACE inhibitors remain foundational. Recombinant natriuretic peptides (nesiritide) had a brief role and have largely been withdrawn from common use.
Apelin agonists and other natriuretic peptide pathway interventions remain investigational. The pathway is mechanistically interesting but has not produced widely-used clinical therapies for hypertension.
Important caveats
Hypertension management should be coordinated by a primary care clinician or cardiologist. Standard care involves lifestyle modification (DASH diet, sodium restriction to <2300 mg/day or lower, regular aerobic exercise, weight optimization, alcohol moderation, smoking cessation) plus appropriate pharmacological therapy. The 2017 ACC/AHA hypertension guideline established blood pressure targets and treatment thresholds. Resistant hypertension may warrant evaluation for secondary causes (renal artery stenosis, primary aldosteronism, pheochromocytoma, sleep apnea).
Peptide therapy is not a substitute for evidence-validated antihypertensive therapy. Patients should not discontinue prescribed antihypertensives in favor of peptide-only approaches. Cardiovascular risk reduction in hypertension comes from sustained blood pressure control, not from peripheral interventions.
None of the peptides discussed is appropriate as primary hypertension therapy in the US. ANP and BNP are biomarkers; recombinant forms have limited clinical use confined to acute heart failure in select markets. Peptide-related research targeting the natriuretic peptide pathway is ongoing but has not produced practical hypertension therapies.
Frequently asked questions
Are there peptides that lower blood pressure?
ANP and BNP are endogenous peptides with vasodilatory and natriuretic effects, but they are not used as antihypertensive therapy in clinical practice. Recombinant BNP (nesiritide) had a brief role in acute heart failure but was largely withdrawn. The peptide-related intervention with the most clinical impact in cardiovascular medicine is sacubitril (the neprilysin inhibitor in Entresto), which prolongs endogenous natriuretic peptide activity — but it is approved for heart failure, not primary hypertension.
Can peptides replace my blood pressure medication?
No. ACE inhibitors, ARBs, calcium channel blockers, and other antihypertensives have decades of RCT evidence with substantial cardiovascular outcome benefit. No peptide has demonstrated comparable efficacy as primary hypertension therapy. Patients should not discontinue prescribed antihypertensives.
What is the role of ANP and BNP in hypertension?
ANP and BNP are best understood as biomarkers and physiological signals rather than therapies. BNP and NT-proBNP are routinely used in heart failure diagnosis and management. Their levels rise with volume overload and provide useful clinical information. Therapeutic use of recombinant forms is limited.
Are there peptide-related drugs for hypertension or heart failure?
Sacubitril/valsartan (Entresto) is the most clinically impactful peptide-pathway drug — sacubitril inhibits neprilysin to prolong endogenous natriuretic peptide activity, combined with the ARB valsartan. PARADIGM-HF showed substantial mortality benefit in heart failure with reduced ejection fraction. Apelin agonists and other natriuretic peptide pathway interventions are in research; no widely used hypertension-specific peptide therapy exists.
Should I get my BNP checked if I have hypertension?
BNP/NT-proBNP testing is most useful in evaluating possible heart failure (suspected based on symptoms like dyspnea, edema), not in routine hypertension management. Hypertension monitoring focuses on blood pressure measurement, end-organ damage assessment (kidney function, retinal exam, ECG), and cardiovascular risk stratification. Discuss any cardiac biomarker testing with your clinician based on specific clinical questions.
Part of these goals
Related conditions
Peptide families relevant to Hypertension
Updated 2026-05-08